NeuroSense Therapeutics is a biotech company developing PrimeC, a novel drug for ALS, a progressive neurodegenerative disorder with a billion-dollar market size. Following outstanding results in pre-clinical studies in two models of ALS zebrafish, NeuroSense has initiated two clinical trials in the US and Israel, to test the efficacy of PrimeC, providing real hope for ALS patients.

PrimeC has been granted orphan drug designation by the FDA and EMA.

We invite you to take part in our program and accelerate the clinical development towards a cure for ALS patients. Scroll down for further information.

You are welcome to leave contact details below, or call us: +972-587-531153

    Investment in NeuroSense

    To date, there is no effective drug for ALS. The available treatments in the market can slightly moderate disease progression, or delay death by only a few months.

    NeuroSense’s drug, PrimeC, targets multiple pathological mechanisms simultaneously and works synergistically in order to slow and perhaps halt disease progression.

    Why Invest in NeuroSense?

    • PrimeC has shown outstanding results in pre-clinical models of ALS, compared to current FDA approved drug Riluzole.
    • The FDA has granted PrimeC an Orphan Designation, allowing 7 years of market exclusivity, as well as financial grants and tax benefits upon commercialization.
    • PrimeC is assembled of a novel formulation of unique doses of two FDA approved drugs with well-known safety profiles, thus the drug can be available for patients within a relatively short time.
    • Pre-clinical studies have been expanded into additional neurodegenerative diseases (i.e. Parkinson).
    • The dedicated and experienced team is working relentlessly to make an effective drug available within 4 years.
    • NeuroSense has a collaborative relationship with the Barrow Neurological Institute, a world-renowned neurological center, for the execution of research and clinical trials.

    Market and Competition

    The ALS drug market is estimated at Billions of dollars for an effective drug which can stop or significantly slow disease progression. There are an estimated 120,000 ALS patients in the western world, and 450,000 patients worldwide. Patient cost per year in the US at late stages of the disease are estimated at $300,000 USD.

    There are several companies at different stages of drug development for ALS, including: Cytokinetics, Biogen, AB Science, KadimaStem, Immunity Pharma, and Amylyx.

    Disease Modifying vs. Symptomatic Treatment

    Many of the available drugs and treatments in development today, treat merely the symptoms, and allow patients only a few extra months of functionality. NeuroSense’s drug aims to drastically slow or even halt disease progression, hence increasing patient’s life expectancy and improving quality of life.

    Molecular Mechanisms vs. Stem Cells

    In contrast to other companies which focus on stem cell treatment, aimed at affecting the system as a whole, NeuroSense emphasizes the underlying multifarious pathological and molecular mechanisms of the disease, in order to pinpoint the treatment effect.

    Pain-Free vs. Invasive Treatment

    Many of the treatments being developed for ALS patients are invasive, intrusive and include extraction and/or injection of cells or other infusions. NeuroSense’s drug comprises of a small, easy-to-use pill to be swallowed, therefore not impairing patient’s quality of life.

    PrimeC, Hope is now a reality